Glucocorticoid-induced Osteoporosis: Pathophysiology And Therapy
E. Canalis, G. Mazziotti, A. Giustina, J. Bilezikian
Published 2007 · Medicine
Download PDFAnalyze on Scholarcy
Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures, which are often asymptomatic, may occur in as many as 30–50% of patients receiving chronic glucocorticoid therapy. Vertebral fractures occur early after exposure to glucocorticoids, at a time when bone mineral density (BMD) declines rapidly. Fractures tend to occur at higher BMD levels than in women with postmenopausal osteoporosis. In human subjects, the early rapid decline in BMD is followed by a slower progressive decline in BMD. Glucocorticoids have direct and indirect effects on the skeleton. The primary effects are on osteoblasts and osteocytes. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes. These effects lead to a suppression of bone formation, a central feature in the pathogenesis of GIO. Glucocorticoids also favor osteoclastogenesis and as a consequence increase bone resorption. Bisphosphonates are effective in the prevention and treatment of GIO. Anabolic therapeutic strategies are under investigation.
This paper references
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
K. Saag (1998)
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
S. Cohen (1999)
Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update.
S. Boonen (2006)
Osteoporosis associated with excess glucocorticoids.
J. Shaker (2005)
Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation
V. Knäuper (1996)
The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis.
T. van Staa (2006)
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
L. Hofbauer (1999)
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
M. Kishimoto (2006)
Skeletal morbidity in inflammatory bowel disease
R. V. van Hogezand (2006)
Rationale for Treatment of Involutional Osteoporosis in Women and for Prevention and Treatment of Corticosteroid-Induced Osteoporosis with Alfacalcidol
E. Schacht (1999)
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
M. Hochberg (2001)
Is bone mineral density predictive of fracture risk reduction?
C. Cefalu (2004)
High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption.
A. Dovio (2006)
Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids.
Z. Wu (1996)
The risk of osteoporosis in Caucasian men and women with obstructive airways disease.
D. Sin (2003)
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.
J. Freije (1994)
The C/EBP family of transcription factors.
A. Wedel (1995)
Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression.
R. Pereira (2002)
Trends in prevention of glucocorticoid-induced osteoporosis.
K. Saag (2006)
Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
E. Buxton (2004)
Clinical utility of microarchitecture measurements of trabecular bone
J. Carballido-Gamio (2006)
Bone structure in patients with low bone mineral density with or without vertebral fractures.
A. Oleksik (2000)
Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial*
D. Reid (2000)
Standards for performing DXA in individuals with secondary causes of osteoporosis.
A. Khan (2006)
Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence.
M. Rubin (2002)
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
J. Tomlinson (2004)
The Vitamin D requirement in health and disease
R. Heaney (2005)
Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis
L. Buckley (1996)
Body composition and vertebral fracture risk in female patients treated with glucocorticoid
H. Kaji (2005)
High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass
K. Natsui (2005)
Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells.
P. Ureña (1994)
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation.
M. Cooper (2001)
Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen.
A. Shiraishi (2000)
Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells.
R. Okazaki (1994)
Effect of cortisol on periosteal and nonperiosteal collagen and DNA synthesis in cultured rat calvariae
E. Canalis (1984)
Perspectives on glucocorticoid-induced osteoporosis.
E. Canalis (2004)
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
D. Glass (2005)
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts.
K. Ohnaka (2005)
Mechanisms of glucocorticoid action in bone.
E. Canalis (2005)
Short-Term Increases in Bone Turnover Markers Predict Parathyroid Hormone-Induced Spinal Bone Mineral Density Gains in Postmenopausal Women with Glucocorticoid-Induced Osteoporosis
N. Lane (2000)
S Amin (2007)
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.
R. Jilka (1999)
Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells
Mei-Fway Iu (2005)
Glucocorticoids Inhibit the Transcriptional Activity of LEF/TCF in Differentiating Osteoblasts in a Glycogen Synthase Kinase-3β-dependent and -independent Manner*
E. Smith (2005)
Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis : 2001 update
S Boonen (2001)
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis
L. Buckley (2001)
Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis
D. Dempster (1983)
Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures.
E. Canalis (1989)
Bone formation by osteocytes.
D. Baylink (1971)
Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone.
A. Giustina (1995)
Predominance of stimulatory effects of interleukin-1 beta on isolated human pancreatic islets.
D. Eizirik (1993)
Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins.
H. Ohmori (2005)
C/EBP regulates hepatic transcription of 11beta -hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways.
L. Williams (2000)
Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy
S. Wallach (2000)
The Epidemiology of Corticosteroid-Induced Osteoporosis: a
T. Staa (2002)
Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy.
H. Gilson (2007)
Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k.
Y. Liu (2004)
Secreted antagonists of the Wnt signalling pathway
Y. Kawano (2003)
Thiazolidinedione use and bone loss in older diabetic adults.
A. Schwartz (2006)
High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
A. Angeli (2006)
Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.
G. Mazziotti (2006)
Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis.
M. Samuels (1993)
Caspases: enemies within.
N. Thornberry (1998)
Prevalence of Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis in Men
Laura M. Cruse (2006)
Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index
E. van Rossum (2003)
Essential Role of β-Catenin in Postnatal Bone Acquisition*
S. Holmen (2005)
Wnt signaling in osteoblasts and bone diseases.
J. Westendorf (2004)
A Randomized Double-blind Placebo-controlled Trial
J. Smith (2004)
The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization
M. Eijken (2006)
Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice.
N. Lane (2006)
Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
E. Romas (2005)
Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.
A. Giustina (1998)
Dexamethasone Enhances Osteoclast Formation Synergistically with Transforming Growth Factor-β by Stimulating the Priming of Osteoclast Progenitors for Differentiation into Osteoclasts*
A. Takuma (2003)
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
T. V. van Staa (2003)
Cortisol Inhibits the Synthesis of Insulin-like Growth Factor-binding Protein-5 in Bone Cell Cultures by Transcriptional Mechanisms (*)
B. Gabbitas (1996)
[Biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP)].
H. Masaki (2006)
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
J. Adachi (2001)
The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.
S. Amin (2002)
Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.
H. Russcher (2005)
Impaired Cortical Bone Acquisition and Osteoblast Differentiation in Mice with Osteoblast-Targeted Disruption of Glucocorticoid Signaling
L. B. Sher (2005)
Glucocorticoids suppress bone formation via the osteoclast.
Hyun-Ju Kim (2006)
Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis.
A. Stellon (1988)
The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults.
E. V. van Rossum (2004)
Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.
S. Bonadonna (2005)
Growth Hormone Response to Growth Hormone-Releasing Hormone Is Reduced in Adult Asthmatic Patients Receiving Long-term Inhaled Corticosteroid Treatment
S. Willsie (2006)
US and UK guidelines for glucocorticoid-induced osteoporosis: Similarities and differences
J. Compston (2004)
Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells.
J. Rubin (1998)
Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia.
R. D. Devlin (2002)
Practice patterns in patients at risk for glucocorticoid-induced osteoporosis
A. Feldstein (2005)
Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures.
S. Rydziel (1995)
Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content
R. Laan (1993)
Essential role of beta-catenin in postnatal bone acquisition.
S. Holmen (2005)
Active acromegaly enhances spontaneous parathyroid hormone pulsatility.
G. Mazziotti (2006)
Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms.
A. Delany (1995)
Osteoblastic cells regulate the haematopoietic stem cell niche
L. M. Calvi (2003)
Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study.
M. Lunt (1997)
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
D. Reid (2000)
Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy.
A. Giustina (1992)
Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis
Q. Rehman (2003)
Glucocorticoid-induced osteoporosis: an update
G. Mazziotti (2006)
Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects.
S. Bonadonna (2005)
Osteoporosis after solid organ and bone marrow transplantation
A. Cohen (2003)
Growth hormone in glucocorticoid-induced osteoporosis.
F. Manelli (2002)
Oral glucocorticoid use is associated with an increased risk of fracture
M. Steinbuch (2003)
Bone resorption by osteoclasts.
S. Teitelbaum (2000)
Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies
R. D. Nijs (2004)
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.
C. O'brien (2004)
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.
N. Lane (1998)
Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study
T. van Staa (2002)
Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae.
E. Canalis (1983)
An Association Between Respiratory Function and Bone Mineral Density in Women from the General Community: A Cross Sectional Study
S. Lekamwasam (2002)
Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation.
S. Ito (2007)
Cortisol Increases Interstitial Collagenase Expression in Osteoblasts by Post-transcriptional Mechanisms (*)
A. Delany (1995)
Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6.
S. Huybers (2007)
Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.
D. Jia (2006)
Episodic secretion of parathyroid hormone in postmenopausal women: assessment by deconvolution analysis and approximate entropy.
M. Samuels (1997)
Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease.
N. Franchimont (2003)
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
K. Saag (1998)
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.
T. V. van Staa (2006)
Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure.
M. Cooper (2002)
CCAAT/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation.
R. Pereira (2004)
This paper is referenced by
5α-Reduced glucocorticoids: a story of natural selection.
Mark Nixon (2012)
Hard Tissue Reconstruction
M. Smith (2013)
Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism
O. Ragnarsson (2012)
Growth hormone, insulin-like growth factors, and the skeleton.
A. Giustina (2008)
Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome.
R. Wetzsteon (2009)
Congenital adrenal hyperplasia.
Selma Feldman Witchel (2011)
Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss
Paul Dennis Miller (2012)
The elderly inflammatory bowel disease patient and osteoporosis
Seymour Katz (2012)
The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy.
Hjalmar Ragnar Agnarsson (2014)
Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases.
I. Tatsuno (2009)
Bone Geometry, Volumetric Bone Mineral Density, Microarchitecture and Estimated Bone Strength in Caucasian Females with Systemic Lupus Erythematosus. A Cross-Sectional Study Using HR-pQCT
S. Hansen (2014)
Bioactivity of dexamethasone-releasing coatings on polymer/magnesium composites.
Fátima Bensiamar (2016)
4.12 – Glucocorticoid Replacement in Man
G M Russell (2017)
Possible mechanisms of prednisolone-induced osteoporosis in zebrafish larva.
Hanliang He (2018)
Management of Glucocorticoid-Induced Osteoporosis
Christian Roux (2019)
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects.
G. Mazziotti (2017)
Exploring the relationship between bone density and severity of distal radius fragility fracture in women
Alvilde Sofie Strand Dhainaut (2014)
Étude descriptive d’une population suivie en consultation présentant des valeurs discordantes de quantité osseuse et de texture osseuse
Sara Kherif-Bouhidel (2018)
Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study
S. Kim (2019)
Glucocorticoid-induced osteoporosis: pathogenesis and prevention
I. G. Krasivina (2020)
Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.
L. Hofbauer (2009)
Bone status in glucocorticoid-treated men and women
E. Leib (2015)
Sclerostin: Therapeutic Horizons Based Upon Its Actions
A. G. Costa (2012)
Therapeutic potentials and modulatory mechanisms of fatty acids in bone
Minyue Bao (2019)
Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis
E. Ramli (2012)
Glucocorticoids and the risk of osteoporosis
L. Caplan (2009)
Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates
B. Aderibigbe (2016)
How effective is risedronate in preventing bone loss in patients on high-dose steroids?
A. Arabi (2008)
Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance.
M. Faienza (2009)
Pharmaceutical care by clinical pharmacists in patients with musculoskeletal disease
Michiel Duyvendak (2010)
Bone Health in Disorders of Sex Differentiation
S. Bertelloni (2010)
Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study.
C. Ohlsson (2011)See more